Objective: A relation between transfusional IOL (iron overload), HFE status and oxidative damage was evaluated. Design, setting and participants: An observational cross-sectional study involving 87 healthy individuals and 78 patients with myelodysplastic syndromes (MDS) with and without IOL, seen at University Hospital of the Federal University of Ceará, Brazil, between May 2010 and September 2011. Methods: IOL was defined using repeated measures of serum ferritin ≥1000 ng/mL. Variations in the HFE gene were investigated using PCR/restriction fragment length polymorphism (RFLP). The biomarkers of oxidative stress (plasmatic malonaldehyde (MDA), glutathione peroxidase (GPx) and superoxide dismutase (SOD)) were determined by sp...
Background/Aims: Hyperferritinemia has been associated with cardiovascular mortality in hemodialysis...
INTRODUCTION: Iron overload is usually observed in patients (even untransfused) with myelodyspla...
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a new disease category...
HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its...
Introduction: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and dys...
Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to...
Myelodysplastic syndromes (MDS) are a group of clonally-acquired blood disorders characterized by in...
Background: HFE gene mutations have been shown to be responsible for hereditary hemochromatosis. The...
Objective: Hemochromatosis is an autosomal recessive disease that is one of the most important reaso...
Iron overload is a potentially life-threatening consequence of multiple red-blood-cell transfusions....
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients...
CONTEXT AND OBJECTIVE: Hemochromatosis is a common inherited disorder of iron metabolism and one of ...
Bei Patienten mit myelodysplastischen Syndromen (MDS) ist die transfusionsbedingte Eisenü...
The clinical experience of the significant difference in iron metabolism between multiple myeloma an...
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients...
Background/Aims: Hyperferritinemia has been associated with cardiovascular mortality in hemodialysis...
INTRODUCTION: Iron overload is usually observed in patients (even untransfused) with myelodyspla...
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a new disease category...
HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its...
Introduction: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and dys...
Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to...
Myelodysplastic syndromes (MDS) are a group of clonally-acquired blood disorders characterized by in...
Background: HFE gene mutations have been shown to be responsible for hereditary hemochromatosis. The...
Objective: Hemochromatosis is an autosomal recessive disease that is one of the most important reaso...
Iron overload is a potentially life-threatening consequence of multiple red-blood-cell transfusions....
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients...
CONTEXT AND OBJECTIVE: Hemochromatosis is a common inherited disorder of iron metabolism and one of ...
Bei Patienten mit myelodysplastischen Syndromen (MDS) ist die transfusionsbedingte Eisenü...
The clinical experience of the significant difference in iron metabolism between multiple myeloma an...
Red blood cell transfusions remain one of the cornerstones in supportive care of lower-risk patients...
Background/Aims: Hyperferritinemia has been associated with cardiovascular mortality in hemodialysis...
INTRODUCTION: Iron overload is usually observed in patients (even untransfused) with myelodyspla...
Acute myeloid leukemia (AML) with myelodysplasia-related changes (AML-MRC) is a new disease category...